Market Trends of Focal Segmental Glomerulosclerosis (FSGS) Treatment Industry
This section covers the major market trends shaping the Focal Segmental Glomerulosclerosis Treatment Market according to our research experts:
Primary FSGS Segment is Expected to Witness High Growth Over the Forecast Period
Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually "idiopathic," referring to the rise of disease without any known, definite, or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. For instance, according to an article published by Springer Nature Limited in January 2021, the Research Group on Progressive Renal Disease from the Ministry of Health, Labor, and Welfare of Japan reported that approximately 800 patients per year were inferred to be diagnosed with FSGS by biopsy in Japan. An international survey revealed that FSGS accounted for 19.1% of primary glomerular disease in North America, 14.9% in Europe, 6.9% in Asia, and 15.8% in Latin America. The current therapy for primary FSGS includes immunosuppressive agents such as glucocorticoids and calcineurin inhibitors. Steroid therapy is one of the most basic and common treatments for oral prednisone.Some of the significant emerging companies with potential drug candidates in the pipeline are Chemocentryx, Reata Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals.
Since it is a rare disease, specialty clinical-stage companies will likely get more funds and are leveraging the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments. So, based on what has been said above, it has been seen that the segment will grow quickly over the next few years.
North America is Expected to Dominate the FSGS Treatment Market Over the Forecast Period
North America accounts for a leading market share because of the presence of a properly structured healthcare industry and the availability of reimbursement policies with wider coverage. There is an increasing prevalence of FSGS; the presence of state-of-the-art healthcare infrastructure; the high adoption rate of new healthcare technology; and the presence of reimbursements are facilitating market growth. For instance, according to an article published by Evaluate Ltd., in December 2021, around 40,000 people in the United States will have FSGS. Furthermore, according to an article published in the November 2021 issue of Clinical Kidney Journal, the high prevalence of renal biopsy registry diagnoses of FSGS potentially points to secondary or genetic causes of FSGS in Mexico. Such an increase in the prevalence of FSGS is expected to drive the market.
Moreover, the United States is among the first choices for several manufacturers to conduct clinical trials. The majority of FSGS clinical trials have occurred or are currently underway in the United States, with universities and research centers heavily involved in funding the trials, which are dominated by drugs under trial. For instance, in December 2021, Vertex Pharmaceuticals Incorporated announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), VX-147 on top of standard of care achieved a statistically significant, substantial, and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline. VX-147 was well tolerated. Based on these results, Vertex plans to advance VX-147 into pivotal development in APOL1-mediated kidney disease, including FSGS, in quarter 1 of FY2022. Several clinical trials and drug approvals for clinical trials are currently underway for FSGS, indicating a high growth rate over the forecast period.
